STAMPEED: Cardiovascular Health Study (CHS)

The primary aim of the study is to conduct a genome-wide association study to identify genetic variants associated with the incidence of myocardial infarction (MI), stroke, and heart failure (HF) among participants enrolled in the Cardiovascular Health Study (CHS) who were free of clinical cardiovascular disease at baseline. The secondary aim is to conduct genome-wide association study of other phenotypes in CHS. The study is an ancillary study to CHS. CHS is a population-based cohort study of risk factors for heart disease and stroke among older adults recruited at 4 US sites in 1989-1990. Subjects underwent an extensive baseline examination, and annual follow-up examinations through 1988-1999.]]>
CHS Manual of Operations: Volume 3 - EventsMethods and manuals: CHS design and CHS event methodsThe four Field Centers of the Cardiovascular Health Study (CHS) are located in Forsyth County, NC; Sacramento County, CA; Washington County, MD; and Pittsburgh, PA. In June 1990, four Field Centers completed the recruitment of 5201 participants. In June 1993, an additional 687 African Americans were recruited using similar methods. Each community sample was obtained from random samples of the Medicare eligibility lists of the Health Care Financing Administration (HCFA). Eligible to participate were persons living in the household of each sampled individual who were: 1) 65 yrs or older; 2) non-institutionalized; 3) expected to remain in the area for 3 yrs; and 4) able to give informed consent. Excluded were those wheelchair-bound, receiving hospice care or cancer treatment. The minority cohort was recruited using similar methods. Participants were eligible whether or not they had clinically apparent cardiovascular disease. For the genome-wide association study, an ancillary study of CHS, participants who had clinical cardiovascular disease at baseline were excluded. Clinical cardiovascular disease was defined as any of the following conditions: coronary heart disease, congestive heart failure, peripheral vascular disease, valvular heart disease, stroke, and transient ischemic attack. Participants were also excluded if they did have available DNA or did not provide written informed consent for genetic studies. Of the 4056 participants eligible for whole genome scans, 3869 had DNA and their scans produced data that passed quality control standards.]]>
CHS is an NHLBI contract-funded cohort study designed to evaluate risk factors for coronary heart disease (CHD) and stroke in older adults. The main objective is to identify factors related to the onset and course of heart disease and stroke. Subjects were recruited (as above) in 1989-90, and were followed with semi-annual contacts, alternating between telephone calls and surveillance clinic visits through 1998-99. During follow-up, 1990-1999, many baseline examination components were repeated, and a few new ones were added. The CHS clinic exams ended in June 1999. After June 1999, when the clinic exams ended, two phone calls per year to participants identified events and collected limited information.]]>